Share: Facebook Twitter LinkedIn
Activity Provided By:

Practicing Clinicians Exchange

Key Updates in the Treatment of HER2-Positive Breast Cancer

Access Activity

Overview / Abstract:

Target Audience

This activity is designed to meet the educational needs of Oncology NPs, PAs, and nurses.

Program Overview

More than half of patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer will develop brain metastases. Several newly approved HER2-targeted drugs with different mechanisms of action are showing promise in this setting, one of which is able to cross the blood-brain barrier. In this activity, a breast cancer specialist looks at current and emerging HER2-targeted therapies, their mechanisms of action, the clinical trials supporting their benefits in patients with metastatic disease, and best practices for managing treatment-related adverse events.

Learning Objectives

Upon completion of this activity, participants should be better able to:

Apply current evidence and guideline recommendations to identify the appropriate use of and optimally sequence HER2-targeted agents in the treatment of HER2-positive metastatic breast cancer
Evaluate emerging research, the mechanisms of action, and the role of novel HER2-targeted therapies in clinical investigation for patients with HER2-positive metastatic breast cancer
Implement best practices for the management of HER2-positive breast cancer brain metastases
Develop strategies to effectively manage adverse events associated with treatments for HER2-positive breast cancer


Aug 14, 2021


Pharmacy CPE



Credits / Hours

CE/CME Credit Hours: 1.00



Presenters / Authors / Faculty


Nicholas McAndrew, MD, MSCE
Clinical Instructor
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California

Beth Sandy, MSN, CRNP
Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Sponsors / Supporters / Grant Providers

Astellas; Astellas and Pfizer; Celgene Corporation; Exelixis; GlaxoSmithKline; Karyopharm Therapeutics; Merck & Co., Inc.; Pharmacyclics LLC, an AbbVie Company; Sanofi Genzyme; Seattle Genetics; and Verastem Oncology

Keywords / Search Terms

Relias LLC Relias LLC., FreeCME., Breast Cancer Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map